KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Cash & Equivalents (2016 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed Cash & Equivalents for 16 consecutive years, with $1.1 billion as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Cash & Equivalents rose 14.99% year-over-year to $1.1 billion, compared with a TTM value of $1.1 billion through Jun 2025, up 14.99%, and an annual FY2024 reading of $966.4 million, up 18.6% over the prior year.
  • Cash & Equivalents was $1.1 billion for Q2 2025 at Alnylam Pharmaceuticals, up from $966.4 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $1.1 billion in Q2 2025 and bottomed at $382.0 million in Q1 2021.
  • Average Cash & Equivalents over 5 years is $830.2 million, with a median of $822.2 million recorded in 2021.
  • The sharpest move saw Cash & Equivalents skyrocketed 119.17% in 2021, then dropped 23.06% in 2022.
  • Year by year, Cash & Equivalents stood at $822.2 million in 2021, then increased by 5.64% to $868.6 million in 2022, then fell by 6.18% to $814.9 million in 2023, then increased by 18.6% to $966.4 million in 2024, then grew by 15.24% to $1.1 billion in 2025.
  • Business Quant data shows Cash & Equivalents for ALNY at $1.1 billion in Q2 2025, $966.4 million in Q4 2024, and $1.1 billion in Q3 2024.